|1.||Garmire, Lana X: 2 articles (01/2015 - 09/2014)|
|2.||Song, Min-Ae: 2 articles (01/2015 - 09/2014)|
|3.||Molnar, Janos: 2 articles (01/2015 - 09/2014)|
|4.||Tiirikainen, Maarit: 2 articles (01/2015 - 09/2014)|
|5.||Ching, Travers: 2 articles (01/2015 - 09/2014)|
|6.||Towner, Dena: 2 articles (01/2015 - 09/2014)|
|7.||Yu, Hong: 2 articles (04/2014 - 01/2013)|
|8.||Franx, A: 2 articles (07/2012 - 07/2012)|
|9.||Yang, Yin: 1 article (06/2015)|
|10.||Yu, Yanhong: 1 article (06/2015)|
06/01/2015 - "Forty-seven patients admitted between January and December, 2012 were enrolled in this study, including 25 patients with early-onset severe preeclampsia (EOPE) and 22 with late-onset severe preeclampsia (LOPE), with 25 women with normal pregnancy serving as control group. "
06/01/2015 - "Serum PIBF in women with severe preeclampsia was positively correlated with placenta PIBF-IOD and negatively with blood Th1/Th2 ratio (P<0.05), but a negative correlation between serum PIBF and 24-hour urinary protein was found only in EOPE group (P<0.05). "
09/01/2014 - "Early onset pre-eclampsia (EOPE) is a disorder that has severe maternal and fetal outcomes, whilst its etiology is poorly understood. "
03/01/2014 - "Placentas from both early-onset (EOPE) and late-onset pre-eclampsia (LOPE) exhibit signs of underperfusion, which in turn, may be associated with altered angiogenesis. "
07/01/2012 - "We report here a series of RAS diagnosed after an early-onset preeclampsia (EOPE). "
|2.||Pregnancy-Induced Hypertension (Hypertension, Pregnancy Induced)
|3.||Birth Weight (Birth Weights)
01/01/2013 - "CffDNA is a potential marker for EOPE, which had a significant reciprocal correlation with babies' birth weight and gestation weeks at delivery. "
07/01/2012 - "The model-predicted detection rates (DR) for fixed 10% false-positive rates were obtained for EOPE and LOPE with or without intra-uterine growth restriction (IUGR,birth weight <10th centile). "
04/01/2014 - "In order to early prevent the onset and development of EOPE, it is necessary to strengthen pregestational and prenatal care for women in these aspects including pregestational BMI ≥ 24 kg/m(2), history of hypertension, diabetes, nephritis, family history of hypertension, and high risk for trisomy 21 syndrom."
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||Pregnancy-Associated Plasma Protein-A (PAPP-A)
|3.||Chorionic Gonadotropin (Human Chorionic Gonadotropin)
|5.||Toll-Like Receptors (Toll-Like Receptor)
|6.||DNA (Deoxyribonucleic Acid)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|10.||Purinergic P1 Receptors (Adenosine Receptor)